Key Takeaways
- PT-141 is a development name commonly associated with bremelanotide, a cyclic melanocortin-receptor agonist studied in premenopausal women.
- The FDA label describes activity at several melanocortin receptor subtypes and says MC1R and MC4R binding is most relevant, but it also states that the clinical mechanism in HSDD is unknown.
- Two phase 3 RECONNECT trials randomized 1,267 premenopausal women and reported statistically significant differences from placebo in validated desire and distress measures.
- The pivotal population had a mean age of 39. Later age-subgroup findings do not establish a perimenopause- or menopause-specific effect.
- Vyleesi is a specific FDA-approved drug product for a narrow premenopausal indication and is not indicated for postmenopausal women. A research-material listing is not interchangeable with that drug product.
- Early, phase 3, safety, review, and animal evidence answer different questions; results should not be transferred across materials, populations, endpoints, or evidence levels.
- Luvi Science PT-141 10mg is listed for laboratory research only. The label quantity is not a dose, route, administration instruction, treatment recommendation, or efficacy claim.
PT-141 research in women centers on bremelanotide, melanocortin-receptor biology, and clinical trials in premenopausal participants with hypoactive sexual desire disorder (HSDD). The evidence supports a real clinical-research history, but it does not establish a menopause-specific benefit, a complete mechanism, or equivalence between Luvi Science research material and the approved Vyleesi drug product.
Research boundary: This article is for scientific education only. Luvi Science materials are for laboratory research only, not for human or veterinary use. This is not medical advice and provides no dosing, route, administration, treatment, combination, efficacy, or safety guidance.
What Is PT-141 (Bremelanotide)?
Names, structure, and material identity
PT-141 is an earlier development name used for bremelanotide. Bremelanotide is a synthetic cyclic peptide related to the melanocortin system. The FDA-approved product Vyleesi contains bremelanotide, while the Luvi Science catalog separately lists PT-141 10mg research material.
Those statements should not be collapsed into “all PT-141 is Vyleesi.” A named active ingredient, an approved finished drug, and a laboratory research material occupy different manufacturing and regulatory contexts. The approved product has defined formulation, controls, labeling, and an indication. The research listing is a catalog material for controlled laboratory work and does not inherit the approved product’s clinical status or instructions.
What “melanocortin agonist” means
An agonist is a molecule that activates a receptor. The FDA label describes bremelanotide as a nonselective melanocortin-receptor agonist, with potency across MC1R, MC4R, MC3R, MC5R, and MC2R. At approved exposure levels, the label identifies binding to MC1R and MC4R as most relevant. That receptor profile is more precise than describing PT-141 as an “MC4R-only peptide.”
How Certain Is the Proposed Mechanism?
MC4R is relevant, but the full clinical pathway remains unresolved
Melanocortin-4 receptor (MC4R) is a G-protein-coupled receptor expressed in several central-nervous-system regions. A 2021 neurobiology review (PMID 33455598) describes a hypothesis in which melanocortin signaling may influence dopamine-linked motivational pathways. The review explicitly draws part of that model from animal research.
The strongest boundary comes from the regulatory source itself: the FDA prescribing information states that the mechanism by which Vyleesi improves HSDD in women is unknown. Therefore, “activates melanocortin receptors” is established pharmacology, while a single complete MC4R-to-desire causal chain remains a proposed explanation rather than a settled clinical mechanism.
A 2025 animal study produced a useful negative result
A female Syrian hamster study (PMID 39793696) examined melanocortin-receptor expression and sexual reward. Bremelanotide did not change measured receptor mRNA in the mesolimbic dopamine system and did not enhance conditioned sexual reward in that test. The authors concluded that their findings did not support action through the tested VTA–nucleus-accumbens reward circuit.
This does not invalidate the human trials. It narrows one mechanistic hypothesis in one animal model. Clinical endpoints, receptor pharmacology, and animal reward assays should be interpreted as related but non-interchangeable evidence.
Evidence Matrix: What Each Source Actually Studied
| Source | Material and population | Design and endpoint | Transfer limit |
|---|---|---|---|
| Diamond et al., 2006 PMID 16839319 |
Bremelanotide; 18 premenopausal women with female sexual arousal disorder | Randomized crossover study; subjective and physiological arousal measures | Small preliminary study; not menopause-specific and not a Luvi catalog-material study |
| RECONNECT, 2019 PMID 31599840 |
Bremelanotide drug product; 1,267 randomized premenopausal women with HSDD | Two phase 3 placebo-controlled trials; validated desire and distress endpoints | Does not establish postmenopausal efficacy, a laboratory-material outcome, or a universal response |
| Age subgroup report, 2022 PMID 35230162 |
1,202 participants in integrated analyses | Prespecified subgroup analyses including age | Age subgroup is not the same as a menopause-stage analysis |
| FDA label, 2019 | Approved Vyleesi drug product | Regulatory indication, pharmacology, warnings, and clinical-study synthesis | Not proof that a research listing is the approved drug or suitable for human use |
| Hamster study, 2025 PMID 39793696 |
Bremelanotide in a female Syrian hamster model | Receptor-expression and conditioned-reward experiments | Animal mechanism results cannot be presented as a human clinical outcome |
This matrix applies the previous Luvi article’s mandatory improvement: every public claim is tied to the exact material, population, sample size, endpoint, and analysis type. It prevents findings from the approved drug formulation or a premenopausal trial from being assigned to a 10mg laboratory listing or a postmenopausal population.
What the Early Human Study Found
Eighteen premenopausal participants and mixed endpoint signals
The 2006 randomized crossover study (PMID 16839319) included 18 premenopausal women with a primary diagnosis of female sexual arousal disorder. Each participant received bremelanotide and placebo in separate study sessions, allowing within-person comparison.
More participants reported moderate or high sexual desire after bremelanotide than after placebo. Among participants who attempted sexual intercourse during the follow-up period, satisfaction with arousal was also higher after bremelanotide. However, the physiological measure of vaginal vasocongestion did not change significantly during the erotic-video assessment.
The mixed result is informative. Subjective desire, perceived arousal, physiological measurements, and distress are not identical endpoints. The study was preliminary, small, premenopausal, and conducted with a defined investigational formulation. It cannot establish an expected outcome for women over 40 or for Luvi’s research material.
What the Phase 3 RECONNECT Trials Found
Design and population
The 2019 publication (PMID 31599840) reports two identically designed phase 3 randomized, double-blind, placebo-controlled trials in premenopausal women with HSDD. Across both studies, 1,267 women were randomized; 1,202 were included in the modified intention-to-treat efficacy population. The mean age was 39, 85.6% of participants were white, and 96.6% were enrolled at U.S. sites.
The coprimary endpoints measured change in the desire domain of the Female Sexual Function Index and change in distress related to low desire. Over 24 weeks, the bremelanotide groups had statistically significant improvements compared with placebo on both endpoint types. Nausea, flushing, and headache were reported more often with bremelanotide.
What “statistically significant” does and does not mean
Statistical significance indicates that the observed group difference met a prespecified statistical threshold under the study model. It does not mean every participant improved, the effect applies to every population, or the trial establishes a menopause-specific result. A 2022 evaluation (PMID 36242769, discussed in the source literature but not used as a primary outcome source here) characterized the overall clinical benefit as modest and highlighted placebo effects and measurement challenges in female-sexual-function trials.
The age-subgroup analysis
A later integrated report (PMID 35230162) examined prespecified subgroups including age, weight, body-mass index, and bioavailable testosterone. It reported statistically significant improvements across several subgroups, with some exceptions. That analysis helps test consistency; it does not become a dedicated perimenopause or postmenopause trial because age and reproductive stage are not interchangeable variables.
Why This Topic Matters to Women Over 40—Without Overclaiming
Midlife readers span different reproductive stages
“Women over 40” can include premenopausal, perimenopausal, and postmenopausal people. The pivotal bremelanotide evidence and FDA indication concern premenopausal women. The label explicitly says Vyleesi is not indicated for HSDD in postmenopausal women. That boundary matters more than a broad age-based marketing claim.
Perimenopause and menopause can prompt questions about desire, sleep, mood, relationships, medications, genitourinary symptoms, and overall health. Those factors are multidimensional. The evidence reviewed here does not show that PT-141 treats menopause symptoms, replaces hormonal evaluation, or has a special effect in women over 40.
Evidence literacy is the appropriate Luvi angle
For midlife readers, the useful question is not “Does this peptide fix menopause-related libido?” It is “Which population was studied, which endpoint changed, what did the regulator approve, and what remains unknown?” Readers exploring adjacent evidence can visit Luvi’s Hormone Research hub and the recent review of menopausal hormone therapy and Alzheimer research. These resources organize research questions; they do not provide personal treatment guidance.
PT-141, Bremelanotide, Vyleesi, and Luvi Material Compared
| Term or material | What it refers to | What should not be inferred |
|---|---|---|
| PT-141 | An earlier development name commonly used for bremelanotide | That every item sold under the name is an approved finished drug |
| Bremelanotide | The generic active-ingredient name used in trials and FDA documents | That every formulation, quantity, or research material is interchangeable |
| Vyleesi | A specific FDA-approved bremelanotide drug product with defined labeling | That its indication or instructions apply to Luvi research material |
| Luvi Science PT-141 10mg | A catalog listing for sealed laboratory research material | A human dose, approved drug identity, treatment, protocol, safety, or efficacy outcome |
The distinction is central to responsible research communication. Clinical-trial evidence can explain why a molecule is scientifically interesting without turning a laboratory listing into a therapeutic product.
Safety and Regulatory Context in the Evidence
The FDA label limits Vyleesi’s indication to acquired, generalized HSDD in premenopausal women under specified diagnostic conditions. It states that the product is not indicated for postmenopausal women or to enhance sexual performance. The label also documents clinically important warnings, contraindications, and adverse reactions.
A blood-pressure study in 397 premenopausal women (PMID 27977473) detected small transient average blood-pressure increases accompanied by heart-rate reductions after bremelanotide in the trial setting. This is safety evidence about a defined drug formulation and protocol, not a basis for self-monitoring instructions or use of research material.
Luvi Science does not translate that record into medical advice. People with sexual-health concerns should consult a qualified healthcare professional. Laboratory researchers should follow institutional approvals, documentation, and material-specific procedures.
Key Terms and Definitions
- PT-141
- A development name commonly associated with bremelanotide.
- Bremelanotide
- A synthetic cyclic melanocortin-receptor agonist studied in female sexual-function research.
- Melanocortin receptor
- A member of a receptor family activated by melanocortin peptides; receptor subtypes have different distributions and functions.
- MC4R
- Melanocortin-4 receptor, a receptor expressed in multiple central-nervous-system regions and investigated in motivation, energy-balance, and sexual-function research.
- HSDD
- Hypoactive sexual desire disorder, the condition evaluated in the pivotal premenopausal bremelanotide trials.
- Premenopausal
- Before menopause; this was the reproductive-stage boundary of the pivotal trials and FDA indication.
- Subgroup analysis
- An analysis asking whether results differ across predefined participant groups; it does not automatically establish a new indication.
Frequently Asked Questions About PT-141 Research in Women
What is PT-141?
PT-141 is an earlier development name for bremelanotide, a cyclic peptide that activates several melanocortin receptor subtypes. Published research and the FDA label discuss bremelanotide, while Luvi Science lists PT-141 10mg as laboratory research material.
Is PT-141 the same as bremelanotide?
PT-141 is commonly used as a development name for bremelanotide. That naming relationship does not make a laboratory catalog material interchangeable with the FDA-approved Vyleesi drug product, which has its own manufacturing, formulation, labeling, and regulatory controls.
Is PT-141 the same as Vyleesi?
Bremelanotide is the active ingredient in Vyleesi, but Vyleesi is a specific FDA-approved drug product. A research-material listing is not the approved product and should not inherit its identity, quality system, indication, or instructions.
How does bremelanotide work?
It activates several melanocortin receptor subtypes, with MC1R and MC4R binding described as most relevant in the FDA label. The label also states that the mechanism by which Vyleesi improves HSDD is unknown, so a complete causal pathway has not been established.
What is the melanocortin-4 receptor?
MC4R is a G-protein-coupled melanocortin receptor expressed in multiple central-nervous-system regions. Reviews and animal studies examine its relationship to motivational and dopamine-linked pathways, but those models do not by themselves prove the clinical mechanism.
What is HSDD?
Hypoactive sexual desire disorder is the clinical condition studied in the pivotal trials. The FDA indication is narrowly defined as acquired, generalized HSDD in premenopausal women when low desire causes marked distress or interpersonal difficulty and is not explained by specified other factors.
What did the RECONNECT trials study?
The two phase 3 RECONNECT trials randomized 1,267 premenopausal women with HSDD. They evaluated changes in validated desire and distress measures over 24 weeks and reported statistically significant differences from placebo, alongside more nausea, flushing, and headache.
Were women over 40 included in bremelanotide trials?
The phase 3 population had a mean age of 39, and later prespecified analyses reported results across age subgroups. Those data do not establish a menopause-specific effect, and the FDA label says Vyleesi is not indicated for postmenopausal women.
Does PT-141 treat menopause-related libido changes?
The evidence reviewed here does not establish PT-141 as a treatment for menopause symptoms or postmenopausal HSDD. Midlife is a useful evidence-literacy context, but it must not be converted into a menopause-specific benefit claim.
Can PT-141 be used with hormone therapy?
The sources reviewed for this article do not establish a general combination recommendation. Hormone-therapy and medication decisions require individualized medical assessment; this research article provides no treatment or combination guidance.
What did the early 2006 study find?
In a crossover study of 18 premenopausal women with female sexual arousal disorder, more participants reported moderate or high desire after bremelanotide than placebo. Vaginal vasocongestion did not change significantly, underscoring that subjective and physiological endpoints can differ.
What does 10mg mean on the Luvi Science listing?
It is the labeled quantity of research material in the catalog listing. It is not a human dose, administration instruction, treatment protocol, equivalence statement, safety claim, or expected outcome.
Sources
- Diamond LE, et al. An effect on subjective sexual response in premenopausal women by bremelanotide. Randomized crossover study; PMID 16839319.
- Kingsberg SA, et al. Bremelanotide for the Treatment of HSDD: Two Randomized Phase 3 Trials. RECONNECT; PMID 31599840.
- Simon JA, et al. Prespecified and Integrated Subgroup Analyses from RECONNECT. PMID 35230162.
- White WB, et al. Ambulatory blood-pressure monitoring and bremelanotide. PMID 27977473.
- Clayton AH, et al. The neurobiology of bremelanotide. Mechanism review; PMID 33455598.
- Bradley C, et al. Female Syrian hamster analyses of bremelanotide. Animal mechanism study; PMID 39793696.
- FDA. Vyleesi (bremelanotide) Prescribing Information. Initial U.S. approval 2019.
PT-141 10mg for Laboratory Research
Qualified laboratories can review Luvi Science PT-141 10mg research material, browse the Intimacy & Wellness research category, or use the Luvi Science Peptide Library to compare research identities and evidence levels. The 10mg label is catalog quantity only—not a dose, route, administration instruction, approved-drug equivalence, treatment recommendation, safety claim, or expected outcome.
Research disclaimer: For laboratory research only. Not intended for human or veterinary use. This article does not constitute medical advice. Luvi Science does not provide dosing, route, administration, treatment, combination, efficacy, or safety guidance.